EIE. R. Israyelyan

E. R. Israyelyan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


E. R. Israyelyan has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Platinum-containing regimens in first-line therapy for cervical cancer: efficacy and safety analysis using a pseudorandomization method

    by Alina V. Trusova, Трусова Алина Владимировна, Румянцев А. А., A. A. Rumyantsev, E. R. Israelyan, Исраелян Э. Р., Царёва А. С., A. S. Tsareva, A. S. Ablyametova, Абляметова А. С., et al.

    Introduction. The current standard of care for metastatic and recurrent cervical cancer (CC) is platinum- and taxane-based chemotherapy (CT). However, the choice of platinum agent remains a subject of debate. Objective. To compare the efficacy of cisplatin- and carboplatin-containing CT regimens in the first-line treatment of advanced CC. Materials and Methods. A multicenter comparative retrospective study using a pseudorandomization method (PSM analysis) was conducted, including patients with metastatic and recurrent CC who received first-line platinum-based therapy (cisplatin or carboplatin) between 2010 and 2025. The use of immunotherapy and bevacizumab in first-line therapy was permitted. Patients who received neoadjuvant/adjuvant CT were excluded. An analysis was performed using the cardinality matching (CM) method with the MatchIT package in R, balancing the groups on key covariates (age, bevacizumab, immunotherapy, history of bleeding, treatment-free interval, and presence of pelvic recurrence) at a 2:1 ratio. The standardized mean difference did not exceed 0.1 in absolute value in all cases. The primary endpoint of the study is progression-free survival (PFS); secondary endpoints are overall survival (OS) and treatment safety. Results. The study included 437 patients. After CM analysis, the carboplatin group included 228 patients, and the cisplatin group included 114 patients. The predominant histotype was squamous cell carcinoma (82.5% and 78.5%, respectively). Stage IV at baseline was observed in 37 (32.5%) and 79 (34.6%) patients. The most common metastatic site was lymph nodes, in 79 (69.3%) and 129 (56.6%) patients, respectively. At a median follow-up of 32.5 (1–141.6) months, median PFS (mPFS) was 8.27 (95% CI 7.7–9.2) mo in the carboplatin group and 8.57 (95% CI 7.5–10.4) mo in the cisplatin group; median OS (mOS) was 23.7 (95% CI 18–35) mo and 33.43 (95% CI 25.5–59.8) mo respectively. No statistically significant difference was found in mPFS (HR 0.84; 95% CI 0.66–1.1; p = 0.185) or mOS (HR 0.76; 95% CI 0.56–1.05; p = 0.100) between the groups. Carboplatin use was associated with a higher incidence of hematologic toxicity (р = 0.301), while cisplatin was associated with more vomiting (р = 0.181), diarrhea (р = 0.359), and nephrotoxicity (р = 0.004). Conclusion. The results of this retrospective study with PSM analysis showed no statistically significant difference in the efficacy of cisplatin versus carboplatin in combination with paclitaxel for metastatic and recurrent CC, with a more favorable toxicity profile for the former platinum agent.

  • Open Access

    Efficacy of pembrolizumab plus lenvatinib versus alternative drug regimens in patients with recurrent endometrial cancer after platinum based chemotherapy: a retrospective cohort study

    by Летучих Ангелина Николаевна, Angelina N. Letuchikh, Румянцев А. А., A. А. Rumyantsev, Исраелян Э. Р., E. R. Israelyan, Абляметова А. С., A. S. Ablyametova, A. V. Trusova, Трусова А. В., et al.

    Introduction. The combination of pembrolizumab and lenvatinib is the preferred second-line treatment for patients with recurrent endometrial cancer (EC) with proficient mismatch repair (pMMR) after platinum-based chemotherapy (CT). However, in real-world clinical practice, this option may be unavailable for some patients. Objective. To evaluate the efficacy of pembrolizumab plus lenvatinib compared with alternative СT regimens in patients with recurrent EC with pMMR tumor status upon progression after platinum based CT. Materials and Methods. A multicenter retrospective cohort study was conducted, including treatment data from patients with advanced and recurrent EC with рMMR tumor status from 37 oncology centers in Russia between December 2020 and December 2025. Patients were assigned to two groups according to the therapy received: immuno-targeted therapy (ITT) consisting of pembrolizumab plus lenvatinib, and alternative CT regimens, which included either platinum-based CT reinduction or non-platinum-based CT. To minimize the impact of baseline characteristic differences between the groups, patients were matched using cardinality matching (matching with maximization of the balanced sample size) at a 1:1 ratio. Group balancing was performed for the following variables: age, histological subtype, stage IV disease, receipt of radical/palliative surgery as first-line treatment, and platinum-free interval (PFI). The standardized mean difference was within ≤0.1 in absolute value for all variables. The primary endpoint was progression-free survival (PFS). Results. A total of 173 patients were enrolled in the study, of whom 106 constituted the ITT group and 67 constituted the CT group. From the initial study population, after cardinality matching, two groups of 67 patients each were formed. The median age was 60 (range, 36–80) years in the ITT group and 61 (range, 37–79) years in the alternative CT group; primary surgery was performed in 61/67 (91%) and 62/67 (93%) of patients, respectively. The median PFI was 6.9 (range, 0.0–106.5) months in the pembrolizumab–lenvatinib combination group and 9.1 (range, 0.0–69.0) months in the control group. At a median follow-up of 36.1 months (95% CI, 31.8–42.6), the median PFS in the ITT group was 9.9 months (95% CI, 7.2–12.9) versus 6.8 months (95% CI, 4.7–8.3) in the alternative CT group, which was statistically significant (HR 0.58; 95% CI, 0.40–0.85; p = 0.005). Conclusions. Treatment with the combination of pembrolizumab and lenvatinib is associated with longer PFS compared with alternative CT regimens in the matched cohort of patients with recurrent and advanced EC with MSS/pMMR tumor status upon progression after platinum-based CT.

  • Open Access

    Comparative effectiveness of carboplatin- versus cisplatin-based first-line chemotherapy in cisplatin-eligible patients with metastatic urothelial carcinoma

    by Абляметова Авашерфе Сапуетовна, Avasherfe S. Ablyametova, Румянцев А. А., A. A. Rumyantsev, E. R. Israelyan, Исраелян Э. Р., Покатаев И. А., I. A. Pokataev, V. I. Evdokimov, Евдокимов В. И., et al.

    Background. Cisplatin-based chemotherapy (CT) is the standard first-line treatment for patients with metastatic urothelial carcinoma (mUC) who meet the Galsky criteria. However, evidence regarding the superior efficacy of cisplatin over carboplatin remains controversial. Objective. To compare the long-term oncological outcomes and toxicity between the two platinum-based regimens. Materials and Methods. This retrospective multicenter study included patients with mUC who were cisplatin-eligible according to the Galsky criteria (eGFR ≥ 60 mL/min/1.73m², ECOG PS 0–1, absence of significant neuro- and ototoxicity). The study also included patients with a borderline eGFR level (40–59 mL/min/1.73 m²), provided they fully met the remaining Galsky criteria. All patients received first-line chemotherapy with either gemcitabine/cisplatin (GemCis) or gemcitabine/carboplatin (GemCarb). A split-dose schedule was permitted for patients with borderline eGFR. Cardinality matching (CM) analysis was performed to balance the groups for key covariates (age, ECOG PS, eGFR, presence of visceral metastases, and maintenance avelumab therapy) in a 1:1 ratio. The primary endpoint was 1-year progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), and safety profile. Results. The initial cohort comprised 221 patients (GemCis, n = 118; GemCarb, n = 103). After CM analysis, two well-balanced groups of 75 patients each were formed. Median follow-up was 18.5 months. No statistically significant difference was observed in PFS between the GemCis and GemCarb groups (21.5% vs. 27.7%; HR 0.86; 95% CI 0.59–1.27; p = 0.462). One-year OS in patients receiving cisplatin- and carboplatin-based regimens was 58% and 62%, respectively (HR 0.96; 95% CI 0.62–1.5; p = 0.882). ORR was also comparable (19% vs. 23%; p = 0.545). Subgroup analysis based on baseline eGFR (40–59 vs. ≥60 mL/min/1.73m²) revealed no differences in long-term outcomes. Cisplatin use was associated with a higher incidence of grade 1–2 nephrotoxicity (59% vs. 33%; p = 0.002) and grade 1–2 nausea/vomiting (30% vs. 6%; p = 0.0003). The rate of grade 3–4 hematological toxicity was comparable between the regimens. Conclusion. In this retrospective study utilizing cardinality matching analysis, the differences in long-term oncological outcomes between cisplatin- and carboplatin-containing regimens were not statistically significant. Furthermore, the cisplatin-containing regimen was associated with a higher incidence of adverse events.

  • Open Access

    Maintenance therapy with avelumab for metastatic urothelial cancer: data from real clinical practice

    by A. S. Ablyametova, A. A. Rumyantsev, E. R. Israelyan, A. N. Lud, T. E. Tikhomirova, A. N. Letuchikh, A. V. Trusova, E. V. Glazkova, V. I. Evdokimov, V. B. Matveev, et al.

    Introduction . Platinum-based chemotherapy (CT) remains the first-line standard of care for metastatic urothelial cancer (mUC). Maintenance therapy with avelumab, based on the JAVELIN Bladder 100 trial, has demonstrated an overall survival (OS) benefit. However, patients in real-world clinical practice often differ from those enrolled in registration trials, which limits the extrapolation of these data. Objective . To demonstrate the long-term outcomes of patients with mUC in real-world clinical practice who are candidates for avelumab maintenance therapy, depending on the management strategy (immunotherapy versus active surveillance), and to evaluate second-line therapy administered upon disease progression in both groups. Materials and Methods . This retrospective multicenter study included platinum-eligible patients aged > 18 years with confirmed mUC who had no disease progression after completing 4–6 cycles of first-line chemotherapy with gemcitabine / cisplatin (GemCis) or gemcitabine / carboplatin (GemCarb). Patients were divided into two groups according to subsequent management: those who received avelumab maintenance therapy and those who were placed under active surveillance. Treatment continued until disease progression or unacceptable toxicity. Upon progression, the choice of subsequent therapy was at the treating physician's discretion. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoint was OS. Results . A total of 115 patients were included in the study. Of these, 70 patients (61 %) received avelumab maintenance therapy, while 45 patients (39 %) were placed under active surveillance. At a median follow-up of 26 months, the 1-year PFS rates were 37.5 % and 16.7 % in the avelumab and surveillance groups, respectively. Median PFS was 6.4 months in the maintenance therapy group and 3.8 months in the surveillance group (HR 0.45, 95 % CI 0.28–0.73; p = 0.0012). The 1-year OS rates were 60.4 % and 53.1 % for patients receiving avelumab and those under surveillance, respectively. Median OS in the above groups was 16.1 months and 12.7 months (HR 0.88, 95 % CI 0.53–1.47; p = 0.65). Disease progression occurred less frequently in the avelumab group (63 % vs. 87 %, p = 0.01), while the proportion of patients who received second-line therapy was higher in this group (68 % vs. 44 %, p = 0.042). In the avelumab group, taxanes (56 %) and platinum-based CT (30 %) were the most common second-line regimens, whereas immunotherapy (76 %) predominated in the surveillance group. Conclusion . Our findings confirm that the strategy of avelumab maintenance immunotherapy after first-line platinum-based chemotherapy for metastatic UC is an effective approach in real-world clinical practice.

  • Open Access

    Surveillance versus retroperitoneal lymph node dissection after induction chemotherapy in patients with seminomatous testicular germ cell tumours metastatic to retroperitoneal lymph nodes: a comparative analysis

    by Ekaterina M. Nikolaeva, Николаева Екатерина Михайловна, E. R. Israelyan, Исраелян Э. Р., G. A. Arakelyan, Аракелян Г. А., I. Ya. Skvortsov, Скворцов И. Я., V. B. Matveev, Матвеев В. Б.

    Background. In 60–80 % of patients with seminomatous testicular germ cell tumours (STGCT) metastatic to the retroperitoneal lymph nodes (RPLN), residual retroperitoneal masses persist after first-line chemotherapy. The optimal management of such patients – surveillance or retroperitoneal lymph node dissection (RPLND) – remains a matter of debate. Aim. To compare progression-free survival (PFS) and overall survival (OS) between surveillance and RPLND in patients with STGCT metastatic to RPLN with an incomplete response to induction chemotherapy. Materials and methods. This retrospective single-centre study included patients with STGCT metastatic to RPLN who received first-line chemotherapy between 2001 and 2025; patients were either kept under surveillance or underwent RPLND. To compare the groups, propensity score matching (PSM) was performed to form a homogeneous subgroup. The primary endpoint was PFS; the secondary endpoint was OS. Results. The analysis included 74 patients: 51 in the surveillance group and 23 in the RPLND group, of whom 5 patients with histologically confirmed seminoma but marker levels (alpha-fetoprotein ≥20 IU/mL and/or β-subunit of human chorionic gonadotropin 1000 mIU/mL) meeting IGCCCG (International Germ Cell Cancer Collaborative Group) criteria for a non-seminomatous tumour were excluded from the analysis; the main analysis therefore comprised 51 patients under surveillance and 18 who underwent RPLND. The groups were comparable for most baseline characteristics; distant metastases (M1) were significantly more common in the RPLND group (27.8 % vs 7.8 %; p = 0.045). RPLND achieved complete resection (R0) in 94.4 % of cases with a complication rate of 5.6 % (no complications ≥Clavien–Dindo IIIa); viable tumour or teratoma was found in 38.9 % of operated patients. PFS did not differ significantly between the groups: the proportion of progression-free patients was 88.9 % in the RPLND group and 96.1 % in the surveillance group (p = 0.277); median PFS was not reached. No difference was observed in the matched subgroup after PSM either (progression 1/8 vs 0/17; p = 0.29). Conclusion. In this Russian cohort of STGCT patients with an incomplete response to induction chemotherapy, no significant differences in PFS or OS were found between patients managed with surveillance and those who underwent RPLND. In patients with a favourable prognosis and residual masses, surveillance appears to be a reasonable management strategy.

  • Open Access

    Analysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)

    by Ya. V. Gridneva, M. I. Volkova, Yu. V. Anzhiganova, V. S. Bragina, В. А. Водолазский, M. I. Gluzman, R. A. Zukov, A. M. Ivanov, E. R. Israelyan, E. V. Karabina, et al.

    Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.


  • Open Access

    dd-MVAC as neoadjuvant chemotherapy for muscle-invasive bladder cancer: a single-center study

    by Tatiana E. Tikhomirova, A. Yu. Anokhin, E. R. Israelyan, А. N. Lud, S. L. Gutorov, N. L. Vashakmadze, G. A. Arakelyan, A. V. Klimov, A. A. Rumyantsev, V. B. Matveev, et al.

    Aim. To evaluate the efficacy, safety, and feasibility of dd-MVAC (methotrexate, vinblastine, doxorubicin, cyclophosphamide) chemotherapy in real-world clinical practice. Materials and methods. Patients were enrolled between September 2022 and May 2025. They were scheduled to receive six cycles of neoadjuvant dd-MVAC chemotherapy, supported by granulocyte colony-stimulating factor from day 4 to day 9 of each cycle, repeated every two weeks. Eligible patients had urothelial bladder cancer staged as cT2–4a, N0–3, M0, with creatinine clearance of ≥50 mL/min. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included toxicity, the number of treatment cycles completed, and pathological response. Results. The study included 40 patients. Of these, 87 % (n = 35) completed six cycles of dd-MVAC, while 8 % (n = 3) and 5 % (n = 2) completed five and four cycles, respectively. Full protocol drug doses were administered to 57 % of patients (n = 23), while a 15 % dose reduction was required in 43 % (n = 17). The majority of these dose reductions (59 %, n = 10) were implemented after the fifth cycle. The most frequent grade 3 adverse events (per Common Terminology Criteria for Adverse Events (CTCAE) v.5.0) were hematological: neutropenia in 40 % (n = 16), anemia in 10 % (n = 4), and thrombocytopenia in 10 % (n = 4). One fatal case of febrile neutropenia occurred. The most common grade 1–2 adverse event was asthenia reported in 80 % (n = 32) of patients. Surgical treatment was performed in 80 % (n = 32) of the cohort. Cystectomy was conducted in 91 % (n = 29) of these surgical patients, while organ-preserving surgery was performed in 9 % (n = 3). A complete pathological response (ypT0pN0) was achieved in 53 % (n = 17) of surgically treated patients, and downstaging to ypT3pN0 was observed in 9 % (n = 3). Disease stabilization was reported in the remaining 38 % (n = 12). No significant decline in renal function was observed; median glomerular filtration rate was 80.4 mL/min/1.73 m2 pre-treatment and 89.1 mL/min/1.73 m2 post-treatment. Conclusion. The dd-MVAC regimen is an effective and feasible neoadjuvant therapy for muscle-invasive bladder cancer, enabling the majority of patients to complete the full preoperative course of chemotherapy.

  • Open Access

    Induction chemotherapy regimens in malignant trophoblastic tumors with high risk of resistance: retrospective study

    by A. S. Tsareva, А. А. Rumyantsev, E. R. Israyelyan, М. N. Tikhonovskaya, А. S. Shevchuk, D. Yu. Frantsev, I. V. Pogrebnyakov, G. S. Yunayev

    Background. High sensitivity of gestational throphoblastic disease (GTD) to chemotherapy makes this disease highly curable, but rapid destruction of tumor can lead to development of life-threatening complications. Low-dose chemotherapy before the main anticancer treatment can reduce these risks, but the effects on long-term outcomes are not sufficiently studied. We conducted a retrospective analysis of the N . N . Blokhin National Medical Research Center of Oncology experience in treating patients with high- and ultra-high risk GTD treated with low-dose induction or full-dose chemotherapy.Materials and methods. The monocenter comparative retrospective study included patients with high or ultra-high risk GTD who received initial treatment in 2000–2023. Patients with rare GTD subtypes, patients who had previously received any chemotherapy were excluded. Patients who received low-dose induction chemotherapy with etoposide + cisplatin comprised the experimental group, while those who received full-dose chemotherapy comprised the control group. After completion of low-dose chemotherapy, standard multidrug chemotherapy was administered until normalization of serum beta human chorionic gonadotropin (β-hCG), followed by consolidation chemotherapy. The primary endpoint of the study was 1-year progression-free survival.Results. The study included 70 patients with GTD, 21 (30 %) patients received low-dose induction chemotherapy. In this group, more patients had ECOG performance status ≥2, clinically significant bleeding, or central nervous system metastases. With median follow-up of 54.6 months, 1-year progression-free survival was 81 % in the low-dose induction chemotherapy group and 90 % in the control group, the differences were not statistically significant (hazard ratio 1.63; 95 % confidence interval 0.46–5.80; p = 0.447). Complete β-hCG response was noted in 16 (77 %) patients in the lowdose induction group and 43 (88 %) patients in control group (p = 0.231). Three-year overall survival rates were 95 % and 98 %, respectively.Conclusion. The results of this retrospective study show no differences in survival of patients with high-risk and ultra-highrisk GTD receiving low-dose induction chemotherapy. In treatment of patients with high risks of complications due to tumor process and/or drug therapy, low-risk induction chemoterhapy should be considered as an option

  • Open Access

    Aspects of hypogonadism in oncological patients receiving antitumor treatment. Literature review

    by M. E. Abramov, E. R. Israelyan, A. S. Tsareva, A. A. Rumyantsev, K. A. Firsov, V. B. Matveev

    Recent development of anticancer drug therapy and the improvement of surgical interventions have led to better oncological treatment outcomes for most patients. The introduction of targeted therapy and immuno-oncological agents into clinical practice has allowed previously incurable diseases to be transformed into chronic conditions. While focusing solely on the effectiveness of therapy, many practicing oncologists often pay little attention to another aspect – toxicity. Hypogonadism is a relatively common adverse event (AE) in men undergoing anticancer treatment. The symptoms of this AE (asthenia, erectile dysfunction, mood variability) are often mistaken for complications of drug therapy. Both chemotherapy (CT) and targeted therapy, as well as immunotherapy, can lead to hypogonadism. According to various authors, platinum-based agents can cause the development of hypogonadism in 50 % of cases among young men. Oxaliplatin-containing regimens may result in a decrease in sperm concentration following adjuvant CT for colorectal cancer. Germ cell tumors of the testis, which have high sensitivity to cisplatin-based CT, are among the most treatable malignant neoplasms, even with metastatic processes. The first stage of treatment for germ cell tumors is orchiectomy, which in itself contributes to the development of hypogonadism. Furthermore, when undergoing CT, the risk of this AE increases significantly, up to 50 % in some publications. Considering that this condition affects men of reproductive age with a very high life expectancy, careful monitoring of total testosterone levels is necessary. Uncorrected hypogonadism can lead to various late AEs: obesity, metabolic syndrome, cardiovascular pathology, and osteopenia.This literature review examines various aspects of hypogonadism in men receiving anticancer treatment and its impact on the development of late complications.

  • Open Access

    TIP regimen (paclitaxel, ifosfamide, cisplatin) in nonseminomatous germ cell tumors with poor-prognosis and unfavorable decline of serum tumor markers: final results

    by E. R. Israelyan, A. A. Tryakin, A. A. Rumyantsev, M. Yu. Fedyanin, P. V. Kononets, S. S. Gerasimov, V. B. Matveev, M. I. Volkova, A. V. Klimov, A. I. Semenova, et al.

    Background: Patients with germ cell tumors (GCTs) and poor-prognosis demonstrate unsatisfactory oncological outcomes, with a one-year progression-free survival (PFS) rate of approximately 50 %. We hypothesized that switching the chemotherapy regimen to TIP (paclitaxel, ifosfamide (mesna), cisplatin) in cases of unfavorable decline of serum tumor markers (STMs) after the first cycle of BEP (bleomycin, etoposide, cisplatin) could improve treatment outcomes in this subgroup of patients.Materials and methods: A multicenter, prospective, non-randomized phase II study included patients with nonseminomatous GCTs and poor-prognosis according to IGCCCG. All patients received the first cycle of chemotherapy in BEP regimen. Patients with an unfavorable decline of STMs subsequently received 4 cycles of TIP regimen (paclitaxel 120 mg / m² on days 1 and 2 + ifosfamide 1500 mg / m² on days 2–5 (+ mesna) + cisplatin 25 mg / m² on days 2–5 + G-CSF). In the presence of residual tumors larger than 1 cm and the technical feasibility of removal, surgical treatment was performed. The primary endpoint was one-year PFS.Results: From 2017 to 2023, 34 patients were included in the study. Enrollment was prematurely closed due to an extremely low likelihood of achieving the primary endpoint. One-year PFS and overall survival (OS) were 57.1 % and 74.4 %, respectively. The favorable response rate (complete response + partial response with normalization STM) was observed in 55,8 % of patients. Disease progression was observed in 21 patients, with the central nervous system being the first site of progression in 8 (37 %) of them. Surgical treatment was performed in 16 patients, with viable tumor obtained in 4 patients. Conducting the first cycle in a “stabilization» mode for ultra-high-risk patients did not affect PFS (p = 0.28) or OS (p = 0.434). The toxicity profile of the TIP regimen was acceptable.Conclusion: Switching from BEP to TIP for patients with nonseminomatous GCTs and an unfavorable decline of STMs did not demonstrate efficacy. Further exploration of alternative therapeutic approaches is needed to improve treatment outcomes.